News

Lenvima is an orally administered molecular targeted agent which inhibits the activities of several different molecules such as VEGFR, FGFR, RET, KIT and PDGFR. Mainly, the agent simultaneously

Gadovist is the first high concentration/high relaxivity gadolinium-based contrast agent to be approved in Japan. In Japan, there are more than 1.6 million MRI procedures conducted each year

The open label, multi-dose, safety and pharmacokinetic (PK) study is expected to enroll around 46 subjects with schizophrenia or schizoaffective disorder. Relday has been designed to offer potentially

Zafatek (trelagliptin succinate) controls blood glucose levels by selectively and continually inhibiting DPP-4, an enzyme that causes the inactivation of glucagon-like peptide-1 and glucagon-dependent insulinotropic polypeptide, incretin hormones

Sovaldi, a once-daily nucleotide analog polymerase inhibitor, is indicated for use in combination with ribavirin (RBV) for 12 weeks and the combination is the first all-oral, interferon-free treatment

The collaboration will help people with Type 1 or Type 2 diabetes to talk to their health care professional (HCP) about these diseases. Merck medical director Mel Kohn

According to the company, Novoeight provides purity, reliability and improved portability, with the highest storage temperature for the longest period of time compared with other marketed recombinant Factor

Encruse is a long-acting muscarinic antagonist (LAMA), a type of bronchodilator which can relax airway muscles and improve airflow in and out of the lungs. The company said

SIG990 is claimed to have the potential to both reduce erythema and decrease the papules and pustules associated with the disease. The company has already secured approval for